These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 29089307)
21. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health. Moreno TA; Kim SJ Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030 [TBL] [Abstract][Full Text] [Related]
22. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor. Giberson M; Taylor V Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977 [No Abstract] [Full Text] [Related]
23. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin). Rhodes C; Harris J; Sulston J; Spanswick C J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806 [TBL] [Abstract][Full Text] [Related]
24. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows. Hawkes N BMJ; 2012 May; 344():e3275. PubMed ID: 22573655 [No Abstract] [Full Text] [Related]
25. Consulting the consultants: Avastin in the treatment of wet AMD. Mohamed R; Saunders DC; Mathews JP Eye (Lond); 2019 Apr; 33(4):529-531. PubMed ID: 30397253 [No Abstract] [Full Text] [Related]
26. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model. Vottonen P; Kankaanpää E Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048 [TBL] [Abstract][Full Text] [Related]
27. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay. Silver J JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863 [No Abstract] [Full Text] [Related]
30. [Avastin-Lucentis: off-label and surroundings]. Messori A Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536 [TBL] [Abstract][Full Text] [Related]
31. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309 [TBL] [Abstract][Full Text] [Related]
32. Minister rules out use of Avastin over Lucentis for wet AMD. Kmietowicz Z BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175 [No Abstract] [Full Text] [Related]
33. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration. Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511 [TBL] [Abstract][Full Text] [Related]
34. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents. Li E; Greenberg PB; Voruganti I; Krzystolik MG R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510 [TBL] [Abstract][Full Text] [Related]
35. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? Lotery A; MacEwen C BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142 [No Abstract] [Full Text] [Related]
36. GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD. Cohen D BMJ; 2015 Apr; 350():h1981. PubMed ID: 25869865 [No Abstract] [Full Text] [Related]
37. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice? Heier JS Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361 [No Abstract] [Full Text] [Related]